DelveInsight’s “Chronic Heart Failure Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Chronic Heart Failure pipeline landscape. It covers the Chronic Heart Failure Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Heart Failure Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Chronic Heart Failure Pipeline? @ https://www.delveinsight.com/sample-requeast/chronic-heart-failure-pipeline-insight

Key Takeaways from the Chronic Heart Failure Pipeline Report

• On June 15, 2026- SQ Innovation Inc. initiated a study aims to compare the pharmacokinetics and bioavailability of intravenous and subcutaneous Furosemide. Although these regimens are not intended to be bioequivalent, they are both expected to achieve therapeutic plasma levels and induce effective diuresis.
• On June 10, 2026- Boehringer Ingelheim conducted a study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before they start on the study. The purpose of this study is to find out whether a medicine called vicadrostat, in combination with another medicine called empagliflozin, helps people with chronic heart failure.
• On May 29, 2026- University Medical Center Groningen announced a study in patients with chronic kidney disease with either cardiovascular disease and/or or heart failure is to compare the effects of the ASi, vicadrostat, with the steroidal MRA, spironolactone, on the change in kidney function from baseline to 4 and 26 weeks.
• On May 22, 2026- Salubris Biotherapeutics Inc. conducted a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure.
• On May 22, 2026- Akros Pharma Inc. initiated a phase 2a study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.
• DelveInsight’s Chronic Heart Failure Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Chronic Heart Failure treatment.
• The leading Chronic Heart Failure Companies such as Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, Ionis Pharmaceuticals, Berlin Cures, CardioCell, Help Therapeutics, Eli Lilly and Company, Chong Kun Dang Pharmaceutical, Antlia Biosciences, Cardiol Therapeutics and others.
• Promising Chronic Heart Failure Therapies such as Ertugliflozin, Metolazone, Levosimendan, JTT-861 Capsules, RLX030 (serelaxin), TSG-01, AZD5462, Pravastatin, rhNRG-1, and others.

Want to know which companies are leading innovation in Chronic Heart Failure? @ Chronic Heart Failure Clinical Trials Assessment

The Chronic Heart Failure Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Chronic Heart Failure Pipeline Report also highlights the unmet needs with respect to the Chronic Heart Failure.

Chronic Heart Failure Overview

Chronic Heart Failure (CHF) is a major public health problem in industrialized societies with an incidence approaching 10 per 1,000 population after age 65 and an age-dependent prevalence of less than 1% between ages 45-55, 2-5% between ages 65-75, and approximately 10% for patients aged 80 years or more. Heart Failure is a complex clinical syndrome characterized by the inability of the heart to provide the cardiac output needed by the organism at normal end-diastolic ventricular pressures. Ventricular dysfunction limits exercise tolerance and may impair the quality of life of affected individuals. Clinically, forward failure of the heart leads to low blood pressure and fatigue, while backward failure results in dyspnea and fluid retention, which may lead to pulmonary congestion, pleural effusions, peripheral edema, as well as impairment of hepatic, gastric, and renal function.

Chronic Heart Failure Emerging Drugs Profile

• Neucardin: Zensun (Shanghai) Sci & Tech

Neucardin is a. Recombinant human neuregulin-1 (Neucardin), developed by Zensun, is a novel genetically engineered biologic used in the treatment of mild and moderate chronic heart failure (CHF). The advantage of Neucardin® is that it can specifically target the cardiac muscle cell, repair the cell structure and improve function during heart contraction and relaxation, thereby improving cardiac function and reversing pathological ventricular remodeling, and significantly reducing death rate and readmission rate while improving the quality of life. In August 2019, Zensun USA, Inc., announced that the investigation of NEUCARDIN, its Recombinant human neuregulin-1 fragment, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of Chronic Heart Failure (CHF). NEUCARDIN, the lead drug candidate from the company’s cardiac therapy program, was also recently granted “priority review” for its conditional approval application in China by the National Medical Products Administration (NMPA) (formerly the CFDA).

• Omecamtiv Mecarbil: Cytokinetics

Omecamtiv mecarbil is an investigational, selective, small molecule cardiac myosin activator, the first of a novel class of myotropes1 designed to directly target the contractile mechanisms of the heart, binding to and recruiting more cardiac myosin heads to interact with actin during systole. Omecamtiv mecarbil is designed to increase the number of active actin-myosin cross bridges during each cardiac cycle and consequently augment the impaired contractility that is associated with heart failure with reduced ejection fraction (HFrEF). Preclinical research has shown that omecamtiv mecarbil increases cardiac contractility without increasing intracellular myocyte calcium concentrations or myocardial oxygen consumption.

• Rexlemestrocel-L (Revascor): Mesoblast

Revascor consists of 150 million mesenchymal precursor cells (MPCs) administered by direct injection into the heart muscle in patients suffering from CHF and progressive loss of heart function. MPCs release a range of factors when triggered by specific receptor-ligand interactions within damaged tissue. Based on preclinical data, it is believed that these factors induce functional cardiac recovery by simultaneous activation of multiple pathways, including induction of endogenous vascular network formation, reduction in harmful inflammation, reduction in cardiac scarring and fibrosis, and regeneration of heart muscle through activation of tissue precursors. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Chronic Heart Failure.

If you’re tracking ongoing Chronic Heart Failure Clinical trials, this press release is a must-read @ Chronic Heart Failure Treatment Drugs

The Chronic Heart Failure Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Heart Failure with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Heart Failure Treatment.
• Chronic Heart Failure Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Heart Failure Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Heart Failure market.

Chronic Heart Failure Companies

Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, Ionis Pharmaceuticals, Berlin Cures, CardioCell, Help Therapeutics, Eli Lilly and Company, Chong Kun Dang Pharmaceutical, Antlia Biosciences, Cardiol Therapeutics and others.

Chronic Heart Failure Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Chronic Heart Failure Products have been categorized under various Molecule types such as,

• Oligonucleotide
• Peptide
• Small molecule

From emerging drug candidates to competitive intelligence, the Chronic Heart Failure Pipeline Report covers it all @ Chronic Heart Failure Market Drivers and Barriers, and Future Perspectives

Scope of the Chronic Heart Failure Pipeline Report

• Coverage- Global
• Chronic Heart Failure Companies- Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, Ionis Pharmaceuticals, Berlin Cures, CardioCell, Help Therapeutics, Eli Lilly and Company, Chong Kun Dang Pharmaceutical, Antlia Biosciences, Cardiol Therapeutics and others.
• Chronic Heart Failure Therapies- Ertugliflozin, Metolazone, Levosimendan, JTT-861 Capsules, RLX030 (serelaxin), TSG-01, AZD5462, Pravastatin, rhNRG-1, and others.
• Chronic Heart Failure Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Heart Failure Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Chronic Heart Failure Treatment landscape in this detailed analysis @ Chronic Heart Failure Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Chronic Heart Failure: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Heart Failure– DelveInsight’s Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Neucardin: Zensun (Shanghai) Sci & Tech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic Heart Failure Key Companies
21. Chronic Heart Failure Key Products
22. Chronic Heart Failure – Unmet Needs
23. Chronic Heart Failure – Market Drivers and Barriers
24. Chronic Heart Failure – Future Perspectives and Conclusion
25. Chronic Heart Failure Analyst Views
26. Chronic Heart Failure Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-heart-failure-pipeline-insight